Zobrazeno 1 - 10
of 158
pro vyhledávání: ''
Publikováno v:
British Journal of Cancer
Background Markers of stromal activation at future metastatic sites may have prognostic value and may allow clinicians to identify and abolish the pre-metastatic niche to prevent metastasis. In this study, we evaluate tenascin-C as a marker of pre-me
Autor:
Marko Bergovec, Andreas Leithner, Mark Goda, Maria Anna Smolle, Laurin Herbsthofer, Susanne Scheipl, Amin El-Heliebi, Martina Tomberger, Christopher Rossmann, Martin Pichler, Pablo López-García, Bernadette Liegl-Atzwanger, Barbara Prietl, Barbara Granegger, Armin Gerger, Joanna Szkandera, Jakob M. Riedl, Iva Brcic
Publikováno v:
Br J Cancer
BACKGROUND: Soft tissue sarcomas (STS) are generally considered non-immunogenic, although specific subtypes respond to immunotherapy. Antitumour response within the tumour microenvironment relies on a balance between inhibitory and activating signals
Autor:
Thomas Steuber, Thorsten Schlomm, Peter T. Scardino, Hans Lilja, Markus Graefen, Sigrid Carlsson, Dirk Pehrke, Daniel Sjöberg, Amy Tin, Alexander Haese, Guido Sauter, Andrew J. Vickers, Hartwig Huland
Publikováno v:
British Journal of Cancer
Background A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may mis
Autor:
Alberto Pavan, Fiorella Calabrese, Laura Bonanno, Lorenza Pasqualini, Paola Del Bianco, Giorgia Nardo, Ilaria Attili, Valentina Guarneri, Alberto Amadori, Giulia Pasello, Martina Verza, Matteo Fassan, Elisabetta Zulato, Stefano Indraccolo, Andrea Boscolo Bragadin, Pierfranco Conte
Publikováno v:
British Journal of Cancer
Background Liquid biopsy has the potential to monitor biological effects of treatment. KRAS represents the most commonly mutated oncogene in Caucasian non-small-cell lung cancer (NSCLC). The aim of this study was to explore association of dynamic pla
Autor:
Takeshi Yamaguchi, Tatsuya Toyama, Yasuaki Sagara, Yukari Uemura, Satoshi Yamashita, Shigeru Imoto, Toshiro Mizuno, Tsutomu Takashima, Hirofumi Mukai, Reiki Nishimura, Tomomi Fujisawa, Shozo Ohsumi, Masato Takahashi, Yasuo Hozumi, Satoshi Fujii, Youngjin Park, Hiromitsu Akabane
Publikováno v:
British Journal of Cancer
Background The effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumour expression after initial therapy, relative to that of standard chemotherapy, has not been evaluated. Methods Patients were randomly assigned to t
Autor:
John F.R. Robertson, Islam M. Miligy, Qing Ting Tan, Michael S. Toss, Emad A. Rakha, Binafsha Manzoor Syed, Hazem Khout, Georgette Oni, Andrew R. Green, Sho Shiino, R. Douglas Macmillan
Publikováno v:
Br J Cancer
British Journal of Cancer
British Journal of Cancer
Background Oestrogen receptor (ER) in invasive breast cancer (BC) predicts response to endocrine therapy (ET) and provides prognostic value. In this study, we investigated the value of ER expression in ductal carcinoma in situ (DCIS) in terms of outc
Autor:
Nayoung Han, Jae Hwan Oh, Hee Jin Chang, Jeongseon Kim, Ji Won Park, Hyun Yang Yeo, Byung Chang Kim, Sun-Young Kong
Publikováno v:
British Journal of Cancer
Background Immunomodulatory cytokines and systemic inflammatory markers are important during cancer development and progression. This study investigated the association and prognostic impact of systemic cytokine profiles and inflammatory markers in c
Autor:
Rebecca Y. Tay, Yvonne Yeung, Niall C. Tebbutt, Carmel Murone, Fiona Chionh, Effie Skrinos, David K. Lau, Jennifer Mooi, John M. Mariadason, Timothy J. Price
Publikováno v:
British Journal of Cancer
BACKGROUND: Advanced biliary tract cancers (BTCs) have a poor prognosis and limited treatment options. This exploratory phase II study aimed to evaluate the activity of the mTOR inhibitor everolimus in advanced BTC and explore prognostic biomarkers.
Autor:
Sachiko Matsuda, Osamu Itano, Ayano Takeuchi, Yoko Fujii-Nishimura, Yuta Abe, Yuki Nakamura, Minoru Kitago, Yutaka Nakano, Masahiro Shinoda, Yuko Kitagawa, Hiroshi Yagi, Taizo Hibi, Yusuke Fujita, Shunichi Imai, Yutaka Endo
Publikováno v:
British Journal of Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) has very poor prognosis despite existing multimodal therapies. This study aimed to investigate whether KRAS mutations at codons 12/13 in cell-free DNA (cfDNA) from preoperative and postoperative ser
Autor:
Edoardo Biondi, Francesca Bergamo, Claudia Mucciarini, Vittorina Zagonel, Enzo Veltri, Monica Ronzoni, Eliana Rulli, Claudio Verusio, Luisa Foltran, F. Galli, Daniele Turci, Francesco Graziano, M. Menghi, Alberto Sobrero, Silvia Lazzarelli, Annalisa Bramati, Vincenzo Ricci, Nicoletta Pella, Sara Lonardi, Irene Bagaloni, Francesca Galli, Mauro Magnani, Maria Teresa Ionta, M. Nicolini, Sandro Barni, A. Ruzzo, Bruno Massidda, R. Labianca, L. Frontini, Pietro Sozzi
Publikováno v:
British Journal of Cancer
Background: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause reduced/abrogated DPD activity. DPYD variants analysis may help for defining individual patients